In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Obesity Week 2025 Medications Cagrilintide: The Peptide That Makes You Forget About Food. I call it the silence between cravings. Cagrilintide is a long acting amylin analog which means it works alongside leptin and GLP 1 to